Physician profile
Anil Sheth
NPI 1790755288
$3,529.59
in general payments reported to CMS, 2019-2025
21 companies · $869 in 2025
The $869 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,487 · 2020: $396 · 2021: $63.45 · 2022: $288 · 2023: $426 · 2025: $869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $869 · Food and Beverage: $426.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $868.63 |
| Food and Beverage | $425.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Research & Development, LLC | $868.63 | 2025 | |
| Janssen Pharmaceuticals, INC | $260.68 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $233.77 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $233.24 | 2020-2023 | Acthar |
| Amgen INC. | $228.50 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $227.15 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $221.81 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $218.03 | 2022-2023 | Opsumit, Uptravi |
| Abbvie INC. | $205.20 | 2022-2023 | Dalvance |
| Paratek Pharmaceuticals, INC. | $201.77 | 2023 | Nuzyra |
| Vifor Pharma, INC. | $141.61 | 2019-2020 | |
| Abbott Laboratories | $126.72 | 2019 | |
| Horizon Therapeutics Plc | $108.37 | 2019 | |
| Insmed, INC. | $106.48 | 2019 | |
| Fresenius USA Marketing, INC. | $57.29 | 2019-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $18.80 | 2019 | |
| Genzyme Corporation | $18.59 | 2019 | |
| Pfizer INC. | $13.89 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.81 | 2019 | |
| Travere Therapeutics, INC. | $12.80 | 2019 | |
| Akebia Therapeutics INC | $12.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Sheth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.